Back to Search
Start Over
Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone-Inhibitory Effect of Octreotide after Growth Hormone-Releasing Hormone Stimulation.
- Source :
-
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2021 Dec; Vol. 379 (3), pp. 400-408. Date of Electronic Publication: 2021 Oct 01. - Publication Year :
- 2021
-
Abstract
- Acromegaly is a chronic systemic disease characterized by facial and peripheral changes caused by soft tissue overgrowth and is associated with multiple comorbidities. Despite available surgical and medical therapies, suitable treatments for acromegaly are still lacking. Efficient drug development requires an understanding of the exposure-response (E-R) relationship based on nonclinical and early clinical studies. We aimed to establish a platform to facilitate the development of novel drugs to treat acromegaly. We evaluated the E-R relationship of the growth hormone (GH)-inhibitory effect of the somatostatin analog octreotide under growth hormone-releasing hormone + arginine stimulation in healthy participants and compared the results with historical data for patients with acromegaly. This randomized five-way crossover study included two placebo and three active-treatment periods with different doses of octreotide acetate. GH secretion in the two placebo periods was comparable, which confirmed the reproducibility of the response with no carryover effect. GH secretion was inhibited by low-, medium-, and high-dose octreotide acetate in a dose-dependent manner. We also examined the E-R relationship in monkeys as a preclinical drug evaluation study and in rats as a more convenient and simple system for screening candidate drugs. The E-R relationships and EC <subscript>50</subscript> values were similar among animals, healthy participants, and patients with acromegaly, which suggests that GH stimulation studies in early research and development allowed simulation of the drug response in patients with acromegaly. SIGNIFICANCE STATEMENT: This study demonstrated similar exposure-response relationships in terms of the growth hormone-inhibitory effect of octreotide after growth hormone-releasing hormone stimulation among healthy participants, monkeys, and rats. The research methods and analyses utilized in this study will be useful for simulating the dosages and therapeutic effects of drugs for acromegaly and will facilitate the research and development of novel therapeutic agents with similar modes of action.<br /> (Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.)
- Subjects :
- Adolescent
Adult
Animals
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Forecasting
Humans
Macaca fascicularis
Male
Rats
Rats, Sprague-Dawley
Receptors, Interleukin-1 antagonists & inhibitors
Receptors, Interleukin-1 blood
Treatment Outcome
Young Adult
Acromegaly blood
Acromegaly drug therapy
Growth Hormone-Releasing Hormone antagonists & inhibitors
Growth Hormone-Releasing Hormone blood
Octreotide therapeutic use
Translational Research, Biomedical methods
Subjects
Details
- Language :
- English
- ISSN :
- 1521-0103
- Volume :
- 379
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The Journal of pharmacology and experimental therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 34599040
- Full Text :
- https://doi.org/10.1124/jpet.121.000769